BIIB

#462
Biogen Inc. - Common Stock
195.9 1 USD
-0.79%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
195.55
198.00
Range Annuel
121.06
205.97
Changement quotidien
-0.79%
Changement Mensuel
+0.96%
Evolution sur 6 mois
+8.75%
Changement Annuel
+48.63%
Clôture Précédente
197.4 7
Open
195.5 5
Low
195.5 5
High
198.0 0
Volume
73
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 28.92 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry Fabricants de Médicaments — Généralités
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
20.02
ratio cours/chiffre d'affaires
2.62

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Nouvelles